Logo.jpg
Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients
06 sept. 2018 08h00 HE | Celsion CORP
OVATION II Study Will Evaluate Initial and Maintenance Dosing of GEN-1 on Progression-Free Survival in a Two-Arm, Randomized Trial of Up to 130 Patients LAWRENCEVILLE, N.J., Sept. 06, 2018 (GLOBE...
Logo.jpg
Celsion Strengthens Its Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for up to $10 Million in Non-Dilutive Funding
04 sept. 2018 08h30 HE | Celsion CORP
 Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...